Development of new fibrinolytic agents

Current Pharmaceutical Design

Volumn 12, Issue 7, 2006, Pages 849-857

  Ueshima, Shigeru ^a,b   Matsuo, Osamu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

bat PA; Endothelial cells; Fibrinolysis; Mutant t PA; scu PA; Staphylokinase; t PA; u PA

Indexed keywords

ALTEPLASE; BUTYLOXYCARBONYLSERYLPROLINE HYDROXIDE; DESMOPRESSIN; DESMOTEPLASE; DIPEPTIDE DERIVATIVE; FIBRIN; FIBRINOLYTIC AGENT; LANOTEPLASE; MONOSODIUM [2 (6 HYDROXYNAPHTHALEN 2 YL) 6 METHYLPYRIMIDIN 4 YLOXY]ACETATE DEHYDRATE; MONTEPLASE; N PALMITOYLSERYLPROLINE HYDROXIDE; N STEAROYL DEXTRO SERYLPROLINE HYDROXIDE; N STEAROYLSERYLPROLINE HYDROXIDE; PAMITEPLASE; PLASMINOGEN ACTIVATOR; PROUROKINASE; PYRIMIDINE DERIVATIVE; RETEPLASE; SARUPLASE; SERYLPROLINE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; VASOPRESSIN DERIVATIVE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BOLUS INJECTION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY RECANALIZATION; DEEP VEIN THROMBOSIS; DISSOLUTION; DOSE RESPONSE; DRUG CLEARANCE; DRUG ERUPTION; DRUG HALF LIFE; ENDOTHELIUM CELL; ENZYME RELEASE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEMOLYSIS; HUMAN; HYPERTENSION; IMMUNOGENICITY; LUNG EMBOLISM; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOEMBOLISM; THROMBOGENESIS; VASCULAR ENDOTHELIUM; VASCULAR PATENCY; ANIMAL; BIOLOGICAL MODEL; DRUG DESIGN; METHODOLOGY; PHARMACEUTICS;

ANIMALS; DRUG DESIGN; FIBRINOLYTIC AGENTS; HUMANS; MODELS, BIOLOGICAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 33645287745     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776056065     Document Type: Review

References (86)

1. Matsuo O. In: Yamaguchi T, Mori K, Minematsu K, del Zoppo GJ Eds, New thrombolytic agents: Basic development. Springer-Verlag Tokyo 1995; 182-7.
2. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
3. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
4. Wiman B, Collen, D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 1997; 78: 19-26.
5. Moroi M, Aoki N. Isolation and characterization of α2-plasmin inhibitor from human plasma. J Biol Chem 1976; 251: 5956-65.
6. Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1987; 272: 549-50.
7. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1984; 301: 214-21.
8. Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 257: 2920-5.
9. Matsuo O, Rijken DC, Cullen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 1981; 291: 590-1.
10. van Zonneveld AJ, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. J Biol Chem 1986; 261: 14214-8.
11. Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acts. 1982; 704: 461-9.
12. Weening-Verhoeff EJ, Quax PH, van Leeuwen RT, Rehberg EF, Marotti KR, Verheijen JH. Involvement of aspartic and glutamic residues in kringle-2 of tissue-type plasminogen activator in lysine binding, fibrin binding and stimulation of activity as revealed by chemical modification and oligonucleotide-directed mutagenesis. Protein Eng 1990; 4: 191-8.
13. Pohl G, Kenne L, Nilsson B, Einarsson M. Isolation and characterization of three different carbohydrate chains from melanoma tissue plasminogen activator. Eur J Biochem 1987; 170: 69-75.
14. Verstraete M. Third-generation thrombolytic drugs. Am J Med 2000; 109: 52-8.
15. Mimuro J, Kaneko M, Murakami T, Matsuda M, Sakata Y. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1. Biochim Biophys Acta 1992; 1160: 325-34.
16. Bennett WF, Paoni NF, Keyt BA, Botstein D, Jones AJ, Presta L, et al. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 1991; 266: 5191-201.
17. Paoni NF, Keyt BA, Refino CJ, Chow AM, Nguyen HV, Berleau LT, et al. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb Haemost 1993; 70: 307-12.
18. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
19. Collen D, Zamarron C, Lijnen HR, Hoylaerts M. Activation of plasminogen by pro-urokinase. II. Kinetics. J Biol Chem 1986; 261: 1259-66.
20. Kasai S, Arimura H, Nishida M, Suyama T. Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260: 12377-81.
21. Kohler M, Sen S, Miyashita C, Hermes R, Pindur G, Heiden M, et al. Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (teu-PA) in patients with acute myocardial infarction. Thromb Res 1991; 62: 75-81.
22. PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989; 1: 863-8.
23. Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. J Am Coll Cardiol 1998; 31: 487-93.
24. Bar FW, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, et al. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. Am J Cardiol 1997; 79: 727-32.
25. Vermeer F, Bosl I, Meyer J, Bar F, Charbonnier B, Windeler J, et al. Saruplase is a safe and effective thrombolytic agent; observations in 1, 698 patients: results of the PASS study. Practical Applications of Saruplase Study. J Thromb Thrombolysis 1999; 8: 143-50.
26. Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, et al. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi. J Cardiovasc Pharmacol 1991; 17: 738-46.
27. Kawai C, Hosoda S, Kimata S, Kanmatsuse K, Suzuki S, Motomiya T, et al. Coronary thrombolysis in acute myocardial infarction of E6010 (Novel modified t-PA): a multicenter, doubleblind, does-finding study. Jpn Pharmacol Ther 1994; 22: 3925-50.
28. Kawai C, Yui Y, Hosoda S, Nobuyoshi M, Suzuki S, Sato H, Takatsu F, et al. A prospective, randomized, double-blind multicenter trial ofa single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group. J Am Coll Cardiol 1997; 29: 1447-53.
29. Inoue T, Yaguchi I, Takayanagi K, Hayashi T, Morooka S, Eguchi Y. A new thrombolytic agent, monteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: initial results of the Combining Monteplase with Angioplasty (COMA) trial. Am Heart J 2002; 144: 673 (135).
30. Ishikawa A, Ohata T, Imamura K, Iwasaki M, Sakai T, Matsuzawa T, et al. Single and repeated intravenous toxicity studies of pamite-plase (genetical recombination) in rats and monkeys. J Toxicol Sci 1997; 22: 117-33.
31. Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y, et al. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. Jpn J Pharmacol 1993; 63: 9-16.
32. Hashimoto K, Oikawa K, Miyamoto I, Hayami Y, Abe Y. Phase I study of a novel modified t-PA. Jpn J Med Pharm Sci 1996; 36: 623-46.
33. Yui Y, Kawai C, Hosoda S, Aoki N, Takano T, Kimmatsuse Y, et al. Randomized, double-blind multicenter trial of YM866 (modified t-PA) by intravenous bolus injection in patients with acute myocardial infarction in comparison with tisokinase (native t-PA). J New Remedies Clin 1996; 45: 2175-2210.
34. Kohnert U, Rudolph R, Verheijen JH, Weening-Verhoeff EJ, Stern A, et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 1992; 5: 93-100.
35. Martin U, von Mollendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther 1991; 50: 429-36.
36. Martin U, von Mollendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator but 06.022 in healthy volunteers. Thromb Haemost 1991; 66: 569-74.
37. Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. Circulation 1995; 91: 2725-32.
38. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 1996; 94: 891-8.
39. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346: 329-36.
40. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
41. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-4.
42. Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J 1999; 137: 786-91.
43. Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 1OB trial. Thrombolysis in Myocardial Infarction (TIMI) 1OB Investigators. Circulation 1998; 98: 2805-14.
44. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-22.
45. Larsen GR, Metzger M, Henson K, Blue Y, Horgan P. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989; 73: 1842-50.
46. den Heijer P, Vermeer F, Ambrosioni E, Sadowski Z, Lopez-Sendon JL, von Essen R, et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 1998; 98: 2117-25.
47. InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-13.
48. Collen D, Silence K, Demarsin E, De Mo M, Lijnen HR., Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis 1992; 6: 203-13.
49. Sako, T. Overproduction of staphylokinase in Escherichia coli and its characterization. Eur J Biochem 1985; 149: 557-563.
50. Gerlach D, Kraft R, Behnke D. Purification and characterization of the bacterial plasminogen activator staphylokinase, secreted by a recombinant bacillus subtilis. Zbl Bakt Mikr Hyg 1988; 269: 314-22.
51. Ueshima S, Silence K, Collen D, Lijnen HR. Molecular conversions of recombinant staphylokinase during plasminogen activation in purified systems and in human plasma. Thromb Haemost 1993; 70: 495-9.
52. Collen D, Schlott B, Engelborghs Y, Van Hoef B, Hartmann M, Lijnen HR, et al. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Biol Chem 1993; 268: 8284-9.
53. McClintock DK, Bell PH. The mechanism of activation of human plasminogen by streptokinase. Biochem Biophys Res Commun 1971; 43: 694-702.
54. Sakai M, Watanuki M Matsuo O. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of α2-plasmin inhibitor. Biochem Biophys Res Commun 1989; 162: 830-7.
55. Lijnen HR, Van Hoef B, Matsuo O, Collen D. On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin and fibrin. Biochim Biophys Acta 1992; 1118: 144-8.
56. Okada K, Yuasa H, Hagiya Y, Fukao H, Ueshima S, Matsuo O. Kinetic analysis of plasminogen activation by staphylokinase/plasminogen complex in the presence of fibrin. Thromb Res 1994; 76: 181-91.
57. Okada K, Nonaka T, Matsumoto H, Fukao H, Ueshima S, Matsuo O. Effects of α2-plasmin inhibitor on plasminogen activation by staphylokinase/ plasminogen complex. Thromb Res 1994; 76: 211-20.
58. Lijnen HR, Van Hoef B, De Cock F, Okada K, Ueshima S, Matsuo O, et al. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991; 266: 11826-32.
59. Okada K, Ueshima S, Takaishi T, Yuasa H, Fukao H, Matauo O. Effects of fibrin and α2-antiplasmin an plasminogen activation by staphylokinase. Am J Hemat 1996; 53: 151-7.
60. Matsuo, O, Okada K, Fukao H, Tomioka Y, Ueshima S, Watanuki M, et al. Thrombolytic properties of staphylokinase. Blood 1990; 76: 925-9.
61. Ueshima S, Okada K, Matsumoto H, Takaishi T, Fukao H, Matsuo O. Effects of endothelial cells on activity of staphylokinase. Blood Coag Fibr 1996; 7: 522-9.
62. Matsumoto H, Ueshima S, Fukao H, Mitsui Y, Matsuo O. Identification of urokinase-type plasminogen activator receptor in human endothelial cells and its modulation by phorbol myristate acetate. Cell Struct Func 1995; 20: 429-37.
63. Lijnen HR, Stassen JM, Vanlinthout I, Fukao H, Okada K, Matsuo O, et al. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemost 1991; 66: 468-73.
64. Shishido, Y, Matsumoto T, Sakai M, Kaneda N, Sansawa H, Shimura K, et al. Fibrin-specific fibrinolysis induced by recombinant staphylokinase. Biol Pharm Bull 1994; 17: 10604.
65. Collen D, De Cock F, Stassen JM. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of staphylokinase and streptokinase in baboons. Circulation 1993; 87: 996-1006.
66. Lijnen HR, Beelen V, Declerck PJ, Collen D. Bio-immunoassay for staphylokinase in blood. Thromb Haemost 1993; 70: 491-4.
67. Vanderschueren S, Barrions L, Kerinchai P, Van den Heuvel P, Hermans L, Vrolix M, et al. for the STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-9.
68. Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaeghe R, Vermylen J, et al. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 1995; 92: 2050-7.
69. Collen D, Sinnaeve P, Demarsin E, Moreau H, De Maeyer M, Jespers L, et al. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction. Circulation 2000; 102: 1766-72.
70. Moreadith RW, Collen D. Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. Adv Drug Deliv Rev 2003; 55: 1337-45.
71. Kratzschmar J, Haendler B, Langer G, Boidol W, Bringmann P, Alagon A, et al. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene 1991; 105: 229-37.
72. Bringmann P, Gruber D, Liese A, Toschi L, Kratzchmar J, Schleuning WD, et al. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995; 270: 25596-603.
73. Toschi L, Bringmann P, Petri T, Donner P, Schleuning WD. Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators. Eur J Biochem 1998; 252: 108-12.
74. Mellott MJ, Stabilito H, Holahan MA, Cuca GC, Wang S, Li P, et al. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb 1992; 12: 212-21.
75. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34: 537-43.
76. Grader AMA, da Costa J, Cash JD. A new vasopressin analogue and fibrinolysis. Lancet 1973; 2: 1417-8.
77. Rosnoblet C, Vischer UM, Gerard RD, Irminger JC, Halban PA, Kruithof EK. Storage of tissue-type plasminogen activator in Weibel-Palade bodies of human endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19:1796-1803.
78. Huber D, Cramer EM, Kaufmann JE, Meda P, Masse J-M, Kruithof EKO, et al. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 2002; 99: 3637-45.
79. Pedersen OD, Gram J, Jespersen J. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease. Thromb Haemost 1995; 73: 835-40.
80. Cugno M, Uziel L, Fabrizi I, Bottasso B, Maggiolini F, Agostoni A. Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion. Thromb Res 1989; 56: 625-34.
81. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-55.
82. Okayama T, Nakano M, Odake S, Hagiwara M, Morikawa T, Ueshima S, et al. Synthetic dipeptide, N-Stearoyl-D-Ser-L-Pro-OEt, induces release of tissue-type plasminogen activator in cultured cells and in experimental animals. Chem Pharm Bull 1994; 42: 1854-8.
83. Ueshima S, Matsuno H, Hayashi M, Horibuchi K, Okada K, Fukao H, et al. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombosis in vivo. Thromb Haemost 2002; 87: 1069-74.
84. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004; 10(1): 39-49.
85. Muro S, Muzykantov VR. Targeting of antioxidant and antithrombotic drugs to endothelial cell adhesion molecules. Curr Pharm Des 2005; 11(18): 2383-401.
86. Nader HB, Lopes CC, Rocha HA, Santos EA, Dietrich CP. Heparins and heparinoids: occurrence, structure and mechanism of antithrombotic and hemorrhagic activities. Curr Pharm Des 2004; 10(9): 951-66.